Displaying drugs 12751 - 12772 of 12772 in total
| Name | Weight | Structure | Description | Categories |
|---|---|---|---|---|
| EP-217609 | 2647.75 C95H151N11O59S8 |  | Not Annotated | Carbohydrates / Coenzymes / Enzymes and Coenzymes / Imidazoles / Polysaccharides |
| Delcasertib | 2880.31 C120H199N45O34S2 |  | Investigated for use/treatment in myocardial infarction. | Protein Kinase C-delta, antagonists & inhibitors |
| Tetracosactide | 2933.49 C136H210N40O31S |  | A diagnostic agent used in the screening of patients presumed to have adrenocortical insufficiency. | Adrenocorticotropic Hormone / Hormones |
| C-peptide | 3020.304 C129H211N35O48 |  | C-peptide is under investigation in clinical trial NCT00278980 (Effect of C-peptide on Diabetic Peripheral Neuropathy). | Amino Acids, Peptides, and Proteins / Blood Glucose Lowering Agents / Hormones / Hormones, Hormone Substitutes, and Hormone Antagonists / Insulin / Pancreatic Hormones / Peptide Hormones / Peptides |
| Aviptadil | 3255.75 C145H232N40O43S |  | Not Annotated | Erectile Dysfunction |
| Vasoactive intestinal peptide | 3326.83 C147H237N43O43S |  | Not Annotated | Gastrointestinal Agents / Neuroprotective Agents / Vasodilating Agents |
| Taspoglutide | 3339.763 C152H232N40O45 |  | Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted... | GLP-1 Agonists |
| Elcatonin | 3363.827 C148H244N42O47 |  | Not Annotated | Calcitonin Preparations |
| Avexitide | 3369.8 C149H234N40O47S |  | Avexitide is under investigation in clinical trial NCT02996812 (Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia). | Glucagon-Like Peptide 1 |
| Calmangafodipir | 3397.468 C110H150Ca4MnN20O70P10 |  | Not Annotated | Contrast Media |
| Ularitide | 3505.926 C145H234N52O44S3 |  | Investigated for use/treatment in congestive heart failure. | Bronchodilator Agents / Diuretics |
| Zilucoplan | 3562.229 C172H278N24O55 |  | A complement inhibitor used to treat generalized myasthenia gravis in anti-acetylcholine receptor (AChR) antibody-positive adults. | Amino Acids, Peptides, and Proteins / Antineoplastic and Immunomodulating Agents / Blood Proteins / Complement Inactivating Agents / Immunoproteins / Immunosuppressive Agents / Peptides / Proteins |
| Cotadutide | 3728.092 C167H252N42O55 |  | Cotadutide is under investigation in clinical trial NCT03444584 (Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Subject With Type 2 Diabetes). | Amino Acids, Peptides, and Proteins |
| Brimapitide | 3822.514 C164H286N66O40 |  | Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers). | Neuroprotective Agents |
| D-JNKI-1 | 3823.498 C164H285N65O41 |  | Investigated for use/treatment in hearing loss. | Neuroprotective Agents |
| Pramlintide | 3949.44 C171H267N51O53S2 |  | An amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy. | Amylin Analog |
| Semaglutide | 4113.641 C187H291N45O59 |  | A glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults. | Glucagon-like peptide-1 (GLP-1) analogues |
| Obinepitide | 4212.78 C185H288N54O55S2 |  | Investigated for use/treatment in obesity. | Not Available |
| Imetelstat | 4610.18 C148H211N68O53P13S13 |  | Imetelstat is under investigation in clinical trial NCT01916187 (Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma). | Enzyme Inhibitors / Telomerase, antagonists & inhibitors |
| Tetracycline phosphate complex | 4821.729 C198H225N18NaO102P10 |  | Not Annotated | Anti-Bacterial Agents |
| Lumefantrine co-artemether | 6116.74 C346H378Cl33N11O16 |  | Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. Lumefantrine Co-Artemether is a tablet formulation of artemether... | Not Annotated |
| HPA-23 | 6685.04 H68N17Na2O86Sb9W21 |  | HPA-23 is an investigational antiviral compound. | Antineoplastic Agents / Antiviral Agents |
Displaying drugs 12751 - 12772 of 12772 in total